Skip to content
Specimen Atlas of Research Peptides30 plates · MIT
PeptidesDBan atlas
Side-by-side · Research reference

BPC-157vsMK-677

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

APhase 2Reviewed9/53 cited
BPhase 2Reviewed13/45 cited
BPC-157
Stable Gastric Pentadecapeptide · Healing
250–500 mcgDaily doseHwang 2016
Phase 2Evidence levelHwang 2016Sikiric 2018
~30 minHalf-life (est.)
SQ or IM · Local · Once or twice daily
MK-677
Oral GHS · Ibutamoren
10–25 mgDaily dose (oral)Nass 2008
Phase 2Evidence levelMurphy 1998Nass 2008
~24 hrHalf-lifeNass 2008
Oral capsule · 1×/day

01Mechanism of Action

Parameter
BPC-157
MK-677
Primary target
VEGFR2 / nitric oxide / FAK-paxillin axes (proposed)Chang 2014Sikiric 2018
Ghrelin receptor (GHS-R1a)Murphy 1998
Pathway
Upregulates VEGFR2 → angiogenesis; modulates NO synthase; promotes fibroblast outgrowth via FAK-paxillinChang 2014
GHS-R1a → Gαq → Ca²⁺ → sustained GH pulses across 24 hrNass 2008
Downstream effect
Accelerated tissue repair, reduced inflammation, improved gut barrier integritySikiric 2018
Sustained GH + IGF-1 elevation; appetite stimulation; lean mass preservationNass 2008
Feedback intact?
No known endogenous receptor; mechanism still under investigation
Pulsatile pattern preserved despite long half-lifeMurphy 1998
Origin
Synthetic pentadecapeptide derived from a sequence in human gastric juice; first characterised by Sikiric et al.Sikiric 2018
Non-peptide spiroindane-piperidine small molecule designed at MerckMurphy 1998
Antibody development
—
—

02Dosage Protocols

Parameter
BPC-157
MK-677
Standard dose
250–500 mcg / dayHwang 2016
Anecdotal community range. Phase 2 trial used 1.0 mg PL-14736 IV/day.
10–25 mg / day oralNass 2008
25 mg used in Nass 2008 elderly trial; 10–15 mg common community dose.
Frequency
Once or twice daily
Split dosing reported anecdotally for chronic injury.
Once daily, oral
Lower / starter dose
200 mcg / day
Conservative starter for new users.
5 mg / day
Evidence basis
Animal-strong + Phase 2 clinicalSikiric 2018Hwang 2016
Phase 2 trials (Nass 2008, Murphy 1998)Nass 2008Murphy 1998
Duration
2–4 weeks (acute injury); 4–8 weeks (chronic)
Anecdotal; no long-term human safety data.
8–16 weeks per cycle (off-cycle to reset receptor sensitivity)
Reconstitution
Bacteriostatic water, 1–2 mL
Oral, no reconstitution
Timing
Local SQ to injury site preferred (anecdotal)
Systemic SQ also used; oral bioavailability shown in animal studies.
Pre-sleep preferred for natural GH pulse alignment
Half-life
~30 min plasma (estimated)
Tissue half-life longer; mechanism may explain durable effect.
~24 hrNass 2008
Once-daily dosing covers 24 hours.

04Side Effects & Safety

Parameter
BPC-157
MK-677
Injection site reaction
Mild irritation (anecdotal)
—
GI symptoms
None reported in PL-14736 Phase 2
—
Cardiovascular
Not reported
No clear adverse signal in trials; congestive heart failure caution
Cancer risk
Theoretical concern via VEGF angiogenesis pathwaySikiric 2018
Contraindicated in active malignancy (GH/IGF-1 axis)
Antibody formation
No data (no long-term human trials)
—
Pregnancy / OB
Avoid — insufficient safety data
Avoid
Long-term safety
Unknown beyond Phase 2 trial duration
—
Drug interactions
None established
—
Increased appetite
—
Strong appetite increase via ghrelin agonism
Water retention
—
Mild edema, paresthesias
Glucose tolerance
—
↑ HbA1c +0.3–0.5% in 2-yr elderly trialNass 2008
IGF-1 elevation
—
+50–100% sustainedNass 2008
Drowsiness
—
Common, especially during initial weeks
Absolute Contraindications
BPC-157
  • ·Pregnancy / breastfeeding
  • ·Known active malignancy (theoretical VEGF concern)
MK-677
  • ·Active malignancy
  • ·Pregnancy / breastfeeding
  • ·Disrupted hypothalamic-pituitary axis
  • ·Congestive heart failure (caution)
Relative Contraindications
BPC-157
  • ·History of cancer
  • ·Concurrent VEGF inhibitor therapy (theoretical)
  • ·Acute thrombotic events
MK-677
  • ·Untreated diabetes
  • ·Pre-diabetes
  • ·Severe insulin resistance

05Administration Protocol

Parameter
BPC-157
MK-677
1. Reconstitution
Add 1–2 mL bacteriostatic water to a 5 mg vial. Roll gently; do not shake. Solution should be clear and colourless.
Capsule or oral solution. No injection.
2. Injection site
Subcutaneous near the injury site is the most common anecdotal route. Systemic SQ (abdomen) also used. Rotate sites.
Oral. Take with or without food.
3. Timing
No strict timing requirement. Most users dose once or twice daily, often morning + evening.
Pre-sleep preferred — aligns with natural GH pulse.
4. Storage
Lyophilised: room temp, light-protected. Reconstituted: refrigerate 2–8 °C, use within 30 days.
Capsule: room temp ≤25 °C, dry place.
5. Needle
27–31G insulin syringe, 4–8 mm. Local injection allows finer 31G.
Monitor HbA1c every 8–12 weeks during chronic use.

06Stack Synergy

BPC-157
+ TB-500
Strong
View TB-500 →

BPC-157 and TB-500 (Thymosin β-4) target distinct healing axes: BPC-157 upregulates VEGF-driven angiogenesis and fibroblast migration; TB-500 increases actin remodelling and cell migration via the actin-sequestering β-thymosin domain. Stacked, they cover both vascular (BPC) and structural (TB-500) regeneration pathways. Anecdotally favoured for tendon and ligament repair where both pathways contribute.

BPC-157
250–500 mcg SQ · daily
TB-500
2 mg SQ · 2× per week
Primary benefit
Tendon/ligament/muscle repair via complementary angiogenesis + migration
MK-677
— no documented stacks